Tripill is a pioneering radiopharmaceutical startup spun off from UNC-Chapel Hill, incorporated in Nov 2022, specializing in the development of targeted radionuclide therapeutic (TRT) agents. 

At the heart of our innovation are powerful linker technology platforms that enable the creation of advanced multifunctional and multitargeting TRT agents. These platforms support the development of a wide range of therapeutic agents, including small molecules, protein, and antibody-based TRT agents.

Our cutting-edge linker technologies have led to the identification of several promising leads targeting diverse biomarkers in oncology. These advancements hold significant potential for improving cancer treatment by enhancing the specificity and efficacy of TRT agents.

Tripill is actively seeking co-development opportunities, technology licensing agreements, and offering fee-for-service radiolabeling of customized ligands utilizing our proprietary technology. Our commitment to excellence and innovation positions us as a leader in the radiopharmaceutical industry, driving forward the future of targeted cancer therapies.